Nonalcoholic fatty liver disease and its prognosis associates with shorter leucocyte telomeres in a 21-year follow-up study

References

• Parthasarathy G, Revelo X, Malhi H. Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun. 2020;4(4):478–492.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.
   PubMed Web of Science ®Google Scholar
• Estes C, Razavi H, Loomba R, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123–133.
   PubMed Web of Science ®Google Scholar
• Adams LA, Anstee QM, Tilg H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–1153.
   PubMed Web of Science ®Google Scholar
• Liu Y, Zhong G, Tan H, et al. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a Meta-analysis. Sci Rep. 2019;9(1):11124–11110.
   PubMed Web of Science ®Google Scholar
• Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–1864.
   PubMed Web of Science ®Google Scholar
• Kirchner H, Shaheen F, Kalscheuer H, et al. The telomeric complex and metabolic disease. Genes-Basel. 2017;8(7):176.
   PubMed Web of Science ®Google Scholar
• Calado RT, Brudno J, Mehta P, et al. Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology. 2011;53(5):1600–1607.
   PubMed Web of Science ®Google Scholar
• Wang Q, Zhan Y, Pedersen NL, et al. Telomere length and all-cause mortality: a Meta-analysis. Ageing Res Rev. 2018;48:11–20.
   PubMed Web of Science ®Google Scholar
• Blackburn EH, Epel ES, Lin J. Human telomere biology: a contributory and interactive factor in aging, disease risks, and protection. Science. 2015;350(6265):1193–1198.
   PubMed Web of Science ®Google Scholar
• Demissie S, Levy D, Benjamin EJ, et al. Insulin resistance, oxidative stress, hypertension, and leukocyte telomere length in men from the Framingham heart study. Aging Cell. 2006;5(4):325–330.
   PubMed Web of Science ®Google Scholar
• Laish I, Mannasse-Green B, Hadary R, et al. Telomere dysfunction in nonalcoholic fatty liver disease and cryptogenic cirrhosis. Cytogenet Genome Res. 2016;150(2):93–99.
   PubMed Web of Science ®Google Scholar
• Zhang M, Hu M, Huang J, et al. Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. Chin Med J. 2019;132(24):2927–2933.
   PubMed Web of Science ®Google Scholar
• Ping F, Li Z, Lv K, et al. Deoxyribonucleic acid telomere length shortening can predict the incidence of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Diabetes Investig. 2017;8(2):174–180.
   PubMed Web of Science ®Google Scholar
• Wojcicki JM, Rehkopf D, Epel E, et al. Shorter leukocyte telomere length in relation to presumed nonalcoholic fatty liver disease in Mexican-American men in NHANES 1999–2002. Int J Hepatol. 2017;2017:8435178.
   PubMed Web of Science ®Google Scholar
• Kim D, Li AA, Ahmed A. Leucocyte telomere shortening is associated with nonalcoholic fatty liver disease‐related advanced fibrosis. Liver Int. 2018;38(10):1839–1848.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zang S, Yang W, et al. Shortened leucocyte telomere length is associated independently with fibrosis stage in non-alcoholic fatty liver disease. Int J Clin Exp Med. 2017;10(7):11204–11212.
   Web of Science ®Google Scholar
• Barnard A, Moch A, Saab S. Relationship between telomere maintenance and liver disease. Gut Liver. 2019;13(1):11–15.
   PubMed Web of Science ®Google Scholar
• Carulli L. Telomere shortening as genetic risk factor of liver cirrhosis. World J Gastroenterol. 2015;21(2):379–383.
   PubMed Web of Science ®Google Scholar
• Nault J, Ningarhari M, Rebouissou S, et al. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat Rev Gastroenterol Hepatol. 2019;16(9):544–558.
   PubMed Web of Science ®Google Scholar
• Donati B, Valenti L. Telomeres, NAFLD and chronic liver disease. Int J Mol Sci. 2016;17(3):383.
   PubMed Web of Science ®Google Scholar
• Dong K, Zhang Y, Huang JJ, et al. Shorter leucocyte telomere length as a potential biomarker for nonalcoholic fatty liver disease-related advanced fibrosis in T2DM patients. Ann Transl Med. 2020;8(6):308.
   PubMed Web of Science ®Google Scholar
• Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397.
   PubMed Web of Science ®Google Scholar
• Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–1554.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and Meta-analysis. Hepatology. 2017;65(5):1557–1565.
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2006. Available from: https://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html
   Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–419.
   PubMed Web of Science ®Google Scholar
• Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology. 2011;53(6):1883–1894.
   PubMed Web of Science ®Google Scholar
• Liu YL, Reeves HL, Burt AD, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309.
   PubMed Web of Science ®Google Scholar
• Dongiovanni P, Petta S, Maglio C, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506–514.
   PubMed Web of Science ®Google Scholar
• Mancina RM, Dongiovanni P, Petta S, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016;150(5):1219–1230.
   PubMed Web of Science ®Google Scholar
• Li Q, Dhyani M, Grajo JR, et al. Current status of imaging in nonalcoholic fatty liver disease. World J Hepatol. 2018;10(8):530–542.
   PubMed Web of Science ®Google Scholar
• Cawthon RM. Telomere length measurement by a novel monochrome multiplex quantitative PCR method. Nucleic Acids Res. 2009;37(3):e21.
   PubMed Web of Science ®Google Scholar
• Méndez-Sánchez N, Arrese M, Zamora-Valdés D, et al. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27(4):423–433.
   PubMed Web of Science ®Google Scholar
• Gehrke N, Schattenberg JM. Metabolic inflammation-A role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? Gastroenterology. 2020;158(7):1929–1947.
   PubMed Web of Science ®Google Scholar
• Pirola CJ, Sookoian S. The dual and opposite role of the TM6SF2-rs58542926 variant in protecting against cardiovascular disease and conferring risk for nonalcoholic fatty liver: a Meta-analysis. Hepatology. 2015;62(6):1742–1756.
   PubMed Web of Science ®Google Scholar
• Antti J, Veikko S, Arpo A. Terveys, toimintakyky ja hyvinvointi suomessa 2011. Tampere, Finland: National Institute  of Health and Welfare; 2011. p. 7–69.
   Google Scholar
• Mather KA, Jorm AF, Parslow RA, et al. Is telomere length a biomarker of aging? A review. J Gerontol A Biol Sci Med Sci. 2011;66(2):202–213.
   PubMed Web of Science ®Google Scholar